- Home
- RIGL vs MATV Comparison
RIGL vs MATV Comparison
Compare RIGL & MATV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | MATV |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 644.7M |
| IPO Year | 2000 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RIGL | MATV |
|---|---|---|
| Price | $40.96 | $12.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $43.20 | $10.00 |
| AVG Volume (30 Days) | ★ 593.7K | 288.6K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 3.17% |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | N/A |
| Revenue | $282,076,000.00 | ★ $1,982,500,000.00 |
| Revenue This Year | $65.53 | $2.62 |
| Revenue Next Year | $0.22 | $2.26 |
| P/E Ratio | $6.58 | ★ N/A |
| Revenue Growth | ★ 79.13 | 0.39 |
| 52 Week Low | $14.63 | $4.34 |
| 52 Week High | $52.24 | $13.57 |
Technical Indicators
Market Signals| Indicator | RIGL | MATV |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 57.35 |
| Support Level | $39.60 | $11.78 |
| Resistance Level | $43.58 | $12.26 |
| Average True Range (ATR) | 3.20 | 0.42 |
| MACD | -1.27 | 0.01 |
| Stochastic Oscillator | 11.83 | 65.25 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About MATV Mativ Holdings Inc.
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments namely Filtration & advanced Materials focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging and healthcare solutions.